Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Upgraded by StockNews.com

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating in a research note issued on Thursday.

Several other research firms have also recently issued reports on KPTI. Robert W. Baird decreased their price target on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 7th. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. Piper Sandler raised their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $3.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $5.00.

Karyopharm Therapeutics Trading Down 3.3 %

Shares of KPTI traded down $0.03 during trading hours on Thursday, reaching $0.84. The company had a trading volume of 395,018 shares, compared to its average volume of 1,256,123. The firm has a 50 day simple moving average of $0.82 and a 200-day simple moving average of $0.90. Karyopharm Therapeutics has a 12-month low of $0.62 and a 12-month high of $1.95. The company has a market capitalization of $104.93 million, a price-to-earnings ratio of -0.73 and a beta of 0.16.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01. The business had revenue of $38.78 million for the quarter, compared to analysts' expectations of $37.86 million. During the same quarter last year, the business posted ($0.30) earnings per share. Sell-side analysts forecast that Karyopharm Therapeutics will post -0.94 earnings per share for the current year.

Institutional Trading of Karyopharm Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC lifted its holdings in Karyopharm Therapeutics by 494.5% in the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company's stock worth $649,000 after purchasing an additional 622,194 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Karyopharm Therapeutics during the 2nd quarter valued at $494,000. GSA Capital Partners LLP grew its stake in Karyopharm Therapeutics by 80.6% in the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock valued at $1,474,000 after buying an additional 792,283 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Karyopharm Therapeutics in the 2nd quarter worth $167,000. Finally, Point72 DIFC Ltd acquired a new stake in Karyopharm Therapeutics in the 2nd quarter worth $31,000. Institutional investors own 66.44% of the company's stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).